Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Rheumatologist: April 2017

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Sneha Patel, MD, Monica Mohile, MD, & Arundathi Jayatilleke, MD  |  April 19, 2017

A 56-year-old African American man presents to the emergency department with polyarthralgias and a fever of 103ºF. One month prior to admission, he presented with right knee pain and swelling. Blood cultures grew S. epidermidis. He was treated for presumed septic arthritis complicated by MSSE bacteremia. He was treated with meropenem and a prolonged course…

Weakness, Fatigue Can Signal Underlying Rheumatologic Disease

Simon M. Helfgott, MD  |  April 17, 2017

As clinicians, we are familiar with pain, stiffness and soreness—subjective nouns that define our métier. These helpful words serve as signposts that direct us along the path to the proper diagnosis. Consider the young man with a stiff, sore back (a case of ankylosing spondylitis?) or the postpartum woman experiencing newly painful, stiff and sore…

seanbear/shutterstock.com

Volunteers Wanted to Join the ACR’s Committees, Board of Directors, Research Foundation

Sharad Lakhanpal, MBBS, MD  |  April 19, 2017

In 1974, President Nixon established a week in April to recognize the importance of volunteering. National Volunteer Week is scheduled for April 23–29 this year. At the College, we like to acknowledge and thank our volunteers year round. The mission of the College cannot be achieved without the time, effort, talent and dedication of our…

The reasons rheumatologists choose hospital or academic employment vary. It comes down to what they value.

Rheumatologists Weigh Pros, Cons of Working in Academia

Karen Appold  |  April 19, 2017

Some rheumatologists find that an option other than working in a private practice makes the most sense for them. The reasons rheumatologists choose hospital or academic employment vary. Individual Choice When Lisa Criscione-Schreiber, MD, MEd, associate professor of medicine and rheumatology training program director, Duke University, Durham, N.C., was finishing her fellowship in 2003, she…

FDA Drug Labeling, Approval Process Help Minimize Lawsuits Against Pharmaceutical Companies

Bruce N. Cronstein, MD  |  April 17, 2017

Like many people, I am up early and in the gym most days. Although I don’t seem to get anywhere new on the stationary bicycle or the elliptical machine, I do get to keep up with the pundits on the early morning talk shows. In contrast to the television series I binge on later in…

Rheumatologists, Social Workers Collaborate to Help Patients with Lupus

Karen Appold  |  April 19, 2017

At the Hospital for Special Surgery (HSS), New York, rheumatologists and social workers have found that an interdisciplinary approach to care for systemic lupus erythematosus (SLE) patients improves the overall patient experience. “Our goal is to help patients navigate the complex healthcare system,” says Jillian Rose, LCSW, MPH, assistant director, Community Engagement, Diversity & Research….

Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

Alvin Lee Day, MD, James W. Fant Jr., MD, & Michael Wagner, MD, FACP, RDMS  |  April 18, 2017

Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

Straightforward Approach Can Help Rheumatology Health Professionals Engage with Fibromyalgia Patients

Terence Starz, MD, on behalf of the ARHP Practice Committee  |  April 19, 2017

“I have pain all over my body” is a challenging response after you’ve asked a new patient what brings them in for their visit. You immediately suspect that this patient has fibromyalgia. The prevalence of fibromyalgia in the U.S. is 5 million people, and it is among the most common conditions in many rheumatology practices….

Fellows Forum Case Report: Neuromyelitis Optica

Atul Kapila, MD, Tayseer Haroun, MBBS, & Jayanth Doss, MD  |  April 19, 2017

Case Presentation The patient was a 42-year-old African American female diagnosed with systemic lupus erythematosus (SLE) based on the findings of polyarthritis, malar and discoid rash, fatigue, positive double-stranded DNA (dsDNA) ribonucleoprotein and Smith antibodies, and low serum complement levels. Her SLE had been well controlled on hydroxychloroquine 400 mg daily, oral methotrexate 25 mg…

New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis

Thomas R. Collins  |  April 19, 2017

WASHINGTON, D.C.—Researchers have identified nine new genetic loci linked with juvenile idiopathic arthritis (JIA), along with evidence that at least some of them likely play a functional role, such as cytokine signaling and T cell expression. The findings were presented in an abstract session at the 2016 ACR/ARHP Annual Meeting, which also included a presentation…

Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety

Thomas R. Collins  |  April 20, 2017

WASHINGTON, D.C.—Challenges abound for the manufacturing of biosimilar drugs—from their sheer size compared with small molecule drugs to the unknowable proprietary aspects of the originator drugs—an expert said at the 2016 ACR/ARHP Annual Meeting in a session titled Immunology Update: Biologic Agents: From Nature to Protein Engineering to Biosimilars. Above all, because biosimilars are copies…

Human Immune System Likened to Model of Military Efficiency

Thomas R. Collins  |  April 20, 2017

WASHINGTON, D.C.—Speaking at the 2016 ACR/ARHP Annual Meeting in a session titled ARHP: Immunology Boot Camp I: Basis of Targeted Therapy, a rheumatologist and immunology expert gave a guided tour of the immune system, described what can go wrong with it and outlined what physicians can do when it does. Troy Torgerson, MD, PhD, associate…

Drug Reduction Strategies, Disease Control for Patients with RA in Remission

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Clinical aspects of managing patients with rheumatoid arthritis (RA) in remission were discussed by a panel of experts at the 2016 ACR/ARHP Annual Meeting during the session titled Rheumatoid Arthritis—Clinical Aspects IV: Managing Patients in Remission. Among the issues raised were strategies to taper or discontinue biologic therapies, as well as clinical predictors of…

Effectiveness of Novel Therapies for Cutaneous SLE Explored

Thomas R. Collins  |  April 20, 2017

WASHINGTON, D.C.—A new, humanized anti-BDCA2 monoclonal antibody can trigger inhibition of the production of interferon, cytokines and chemokines derived from plasmacytoid dendritic cells in patients with cutaneous systemic lupus erythematosus (SLE), according to research presented at the 2016 ACR/ARHP Annual Meeting. The findings were discussed during a session on SLE treatment, drug adherence and the…

Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

Studies Highlight Risk of Damage from Lupus Treatments

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

Ethics Forum: Teach Rheumatology Fellows to Use Good Judgment in Pharmaceutical Company Interactions

Arundathi Jayatilleke, MD, MS  |  April 19, 2017

We teach medical students, residents and fellows evidence-based medicine to lay the groundwork for rational prescribing and good clinical judgment. But should we stop our rheumatology fellows from interacting with pharmaceutical companies as part of this foundation? It is not surprising that pharma­ceutical companies can influence physician pre­scribing through gifts. At least, it should not…

How to Bill Medicare Patients for Non-Covered Services

Steven M. Harris, Esq.  |  April 19, 2017

What do you do when you are presented with a patient who needs treatment but the patient’s insurance company will not pay for the services? Can you provide the services anyway? Who will pay for them? How do you collect payment for such services? If the patient consents to receive the services in spite of…

Salsa Dancing Gives Medical Instructor Confidence Boost

Carol Patton  |  April 19, 2017

Alyssa B. Dufour, PhD, is a salsa dancing junkie. Besides taking weekly dance lessons, she salsa dances three times a week at local clubs or studios and practices routines around the house—while cooking dinner, getting dressed or watching TV. She can’t seem to get enough of the social dance that has boosted her confidence in…

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2017

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Rheumatology Research Foundation Fundraising Campaign Exceeds $60M Goal

From the College  |  April 17, 2017

The Rheumatology Research Foundation’s largest fundraising campaign, Journey to Cure, has surpassed its $60 million fundraising, raising a grand total of $61,430,466. With the support of 3,869 donors, the campaign has funded awards for more than 900 rheumatology professionals. “The success of Journey to Cure demonstrates the commitment rheumatologists and health professionals have to impacting…

Participate in Virtual Capitol Hill Meetings with the ACR

From the College  |  April 17, 2017

On May 11, ACR leadership representatives from the Board of Directors, the Affiliate Societies Council and the Committee on Government Affairs and RheumPAC will take the ACR’s policy messages to Capitol Hill for the Advocacy Leadership Conference. There is power in numbers, so we hope you will participate in our Virtual Hill Day by visiting…

Rheumatology Case Report: Bullous Lesions in Patient with Lupus

Mitali Sen, MD, Corrado Minimo, MD, & Ruchika Patel, MD  |  April 20, 2017

Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with multiple acute or chronic cutaneous manifestations, including the relatively rare category of bullous lupus. The development of vesiculo-bullous lesions may be associated with a high morbidity, hence they warrant an urgent investigation, including a skin biopsy to identify the diagnosis and initiate prompt treatment. With…

Use Time Component When Coding Counseling, Coordination of Care Visits

From the College  |  April 17, 2017

Although there are seven components for the levels of evaluation and management (E/M) services, most encounter levels are coded on the basis of the history, examination and medical decision making (MDM), which are the key components extracted from documentation in the medical record. However, when counseling and coordination of care for a patient are the…

Rheumatology Coding Corner Question: Billing Infusion Procedure with JW Modifier

From the College  |  April 20, 2017

An 82-year-old female established patient diagnosed with ankylosing spondylitis in multiple joints returns to the office for her second infliximab infusion. She denies any fevers, cough or concurrent illness. Her joint pain is 7 on a scale of 1–10. She complains of achy pain in the cervical, lumbar and sacral regions of her spine. She…

Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

From the College  |  April 20, 2017

Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This E/M service entailed the…

Issue Archive

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences